세계의 감마나이프 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2032년)

Gamma Knife Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032

US $ 4,995 ￦ 7,088,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,352,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 12,055,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

Persistence Market Research는 최근 세계 감마나이프(Gamma Knife) 시장에 대한 상세한 조사 보고서를 발표하여 촉진요인, 동향, 기회, 과제 등 시장 역학에 대한 상세한 통찰력을 제공했습니다. 이 보고서는 특히 비침습적 신경외과 치료에 초점을 맞춘 헬스케어 및 의료기기 분야의 이해관계자들에게 시장 구조와 미래 전망에 대한 종합적인 이해를 제공하는 것을 목표로 하고 있습니다.

주요 인사이트

• 세계 시장 매출(2022년) : 2억 410만 달러
• 추정 시장 규모(2033년) : 31억 1,140만 달러
• 세계 시장 성장률(2022-2033년 CAGR) : 4.8%

감마나이프 세계 시장 : 조사 범위

감마나이프 시장은 주로 뇌종양, 혈관 기형 및 기타 신경 질환 치료에 사용되는 비침습적 수술 도구인 감마나이프 기계의 생산, 유통 및 사용에 초점을 맞추었습니다. 이 시장에는 주변 건강한 조직에 미치는 영향을 최소화하면서 복잡한 뇌 질환을 치료할 수 있는 정밀 방사선 수술을 통해 환자의 예후를 개선하는 것을 목표로 하는 다양한 제품과 서비스가 포함됩니다.

시장 성장의 촉진요인:

뇌종양 유병률 증가와 다양한 병용치료법 소개

뇌종양 발생률 증가와 치료법의 발전으로 감마나이프 시장의 성장을 가속하고 있습니다. 미국 암협회에 따르면 뇌종양은 암 중 8번째로 흔한 암이며, 40세 이상 암 사망 원인 중 3위를 차지합니다. 세계 인구의 고령화와 확대에 따라 감마나이프 방사선 수술을 포함한 효과적인 뇌종양 치료에 대한 수요가 증가할 것으로 예상됩니다.

감마나이프 방사선 수술은 주변의 건강한 뇌 조직을 보존하는 고도로 표적화된 치료법으로, 특히 다발성 뇌전이가 있는 환자에게 적합합니다. 감마나이프 방사선 수술과 생물학적 또는 면역학적 약물을 병용하는 치료법도 인기를 끌고 있습니다. 예를 들어, Elekta의 흑색종 뇌전이에 대한 병용요법은 면역요법과 감마나이프 방사선 수술의 조합으로 종양 조절과 환자 생존율을 개선하는 것으로 나타나 병용요법이 시장 성장을 가속할 수 있는 잠재력을 강조하고 있습니다.

규제 당국의 승인 및 신제품 출시

감마나이프 시장은 규제 당국의 승인과 혁신적인 제품 채택에 의해 더욱 뒷받침되고 있습니다. 예를 들어, Elekta는 2022년 5월에 Icon을 발표했습니다. 이 감마나이프 시스템은 프레임이 없는 마스크 기반 방사선 수술을 제공함으로써 이 분야에 혁명을 일으켰습니다. 이 시스템은 특히 호주와 같은 지역에서 큰 반향을 일으켜 신경 질환 치료를 위한 뇌 SRS 능력을 확장하고 시장 성장을 가속하고 있습니다.

시장 과제:

감마나이프 방사선 치료 장비의 높은 비용과 환자의 낮은 의식 수준

감마나이프 시장이 직면한 중요한 과제 중 하나는 감마나이프 장비의 높은 비용과 그에 따른 투자 및 유지보수 비용입니다. 감마나이프 장비의 초기 비용은 다른 방사선 장비에 비해 상당히 높기 때문에 신흥국에서의 도입이 제한적입니다. 예를 들어, 인도의 감마나이프 수술은 6,500달러부터 시작하지만, 유럽과 미국에서는 4만 달러에서 7만 달러에 달할 전망입니다. 또한 감마나이프 장비에 사용되는 코발트60 방사선원은 100만 달러에서 200만 달러에 달하며, 5년마다 교체해야 하기 때문에 전체 비용 지출을 증가시킵니다.

또한 북미와 유럽 이외 지역에서는 감마나이프 장비의 가용성이 제한되어 있고, 장비를 조작할 수 있는 숙련된 전문가가 부족하다는 점도 시장 성장을 저해하고 있습니다. 또한, 감마나이프 치료에 대한 대중의 인식이 여전히 낮고, 많은 환자들이 감마나이프 치료의 이점을 알지 못하거나 치료법에 대한 오해를 가지고 있는 경우가 많습니다. 이러한 인식과 이해 부족은 특히 첨단 의료 기술에 대한 접근성이 제한적인 지역에서 시장 성장을 둔화시킬 것으로 예상됩니다.

본 보고서에서 다룬 주요 질문들

• 세계 감마나이프 시장의 성장을 가속하는 주요 요인은?
• 감마나이프 치료 도입을 주도하는 소비자층은?
• 방사선 수술 기술의 발전은 경쟁 구도에 어떤 영향을 미쳤는가?
• 세계 감마나이프 시장에서 주요 기업은 어디에 있으며, 시장 지위를 유지하기 위해 어떤 전략을 취하고 있는가?
• 세계 감마나이프 시장의 새로운 트렌드와 전망은?

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위/분류
• 시장의 정의/범위/제한
• 포함 사항 및 제외 사항

제3장 주요 시장 동향

• 시장에 영향을 미치는 주요 동향
• 제품 혁신/개발 동향

제4장 주요 성공 요인

• 제품 채택/사용 상황 분석
• 제품 USP/특징
• 설치 기반 시나리오
• 기술 평가
• 규제 상황
• PESTLE 분석
• Porter's Five Forces 분석
• 밸류체인 분석

제5장 시장 배경

• 거시경제 요인
• 예측 요인 - 관련성과 영향
• 역학

제6장 COVID-19 위기 - 영향 평가

• COVID-19와 영향 분석
  • 질환별
  • 치료 대상 장기별
  • 지역별
• 2024년 시장 시나리오

제7장 세계 시장 수요(금액 또는 규모, 백만 달러) 분석

• 과거 시장 매출(백만 달러) 분석, 2019년-2023년
• 현재 및 향후 시장 매출(백만 달러) 예측, 2024년-2032년
  • 전년대비 성장 동향 분석
  • 절대액 기회 분석

제8장 세계 시장 분석 : 질환별

• 서론/주요 조사 결과
• 과거 시장 규모(백만 달러) 분석 : 질환별, 2019-2023년
• 현재 및 향후 시장 규모(백만 달러) 분석과 예측 : 질환별, 2024년-2032년
  • 뇌전이
  • 암
  • 동정맥 기형(AVM)
  • 삼차 신경통
  • 기타
• 시장의 매력 분석 : 질환별

제9장 세계 시장 분석 : 치료 대상 장기별

• 서론/주요 조사 결과
• 과거 시장 규모(백만 달러) 분석 : 치료 대상 장기별, 2019-2023년
• 현재 및 향후 시장 규모(백만 달러) 분석과 예측 : 치료 대상 장기별, 2024년-2032년
  • 머리
  • 목
  • 기타
• 시장의 매력 분석 : 치료 대상 장기별

제10장 세계 시장 분석 : 지역별

• 서론
• 과거 시장 규모(백만 달러) 분석 : 지역별, 2019-2023년
• 현재 및 향후 시장 규모(백만 달러) 분석과 예측 : 지역별, 2024년-2032년
  • 북미
  • 라틴아메리카
  • 유럽
  • 남아시아
  • 동아시아
  • 오세아니아
  • 중동 및 아프리카(MEA)
• 시장의 매력 분석 : 지역별

제11장 북미 시장 분석

제12장 라틴아메리카 시장 분석

제13장 유럽 시장 분석

제14장 남아시아 시장 분석

제15장 동아시아 시장 분석

제16장 오세아니아 시장 분석

제17장 중동 및 아프리카 시장 분석

제18장 시장 구조 분석

• 시장 분석 : 기업 Tier별
• 주요 기업의 시장 점유율 분석
• 시장 입지 분석

제19장 경쟁 분석

• 경쟁 대시보드
• 경쟁 벤치마킹
• 경쟁 상세 정보
  • Elekta AB
  • Varian Medical Systems
  • Huiheng Medical, Inc.
  • MASEP Medical Science Technology Development(Shenzhen) Co., Ltd.
  • Akesis Inc.
  • Cyber Medical Corporation Limited.
  • Masep Infini Global, Inc.
  • Nordion, Inc.
  • Hokai
  • ET Medical Group
  • American Shared Hospital Services

제20장 사용된 전제조건과 두자어

제21장 조사 방법

LSH

영문 목차

영문목차

Persistence Market Research has recently published an in-depth report on the global gamma knife market, offering detailed insights into market dynamics, including drivers, trends, opportunities, and challenges. This report aims to provide a comprehensive understanding of the market structure and future outlook, particularly for stakeholders in the healthcare and medical device sectors focused on non-invasive neurosurgical treatments.

Key Insights:

• Global Market Revenue (2022): US$ 204.1 Million
• Estimated Market Value (2033): US$ 311.4 Million
• Global Market Growth Rate (CAGR 2022-2033): 4.8%

Global Gamma Knife Market - Report Scope:

The gamma knife market focuses on the production, distribution, and use of gamma knife machines, a non-invasive surgical tool primarily used for treating brain tumors, vascular malformations, and other neurological disorders. This market encompasses a range of products and services aimed at improving patient outcomes through precision radiosurgery, which allows for the treatment of complex brain conditions with minimal impact on surrounding healthy tissues.

Market Growth Drivers:

Rising Prevalence of Brain Tumors Coupled with Introduction of Various Combination Treatment Therapies

The rising incidence of brain tumors, coupled with advancements in treatment modalities, is driving the growth of the gamma knife market. According to the American Cancer Society, brain tumors are the eighth most prevalent type of cancer and the third leading cause of cancer deaths in people aged 40 and older. As the global population ages and expands, the demand for effective brain tumor treatments, including gamma knife radiosurgery, is expected to increase.

Gamma knife radiosurgery offers a highly targeted treatment option that spares surrounding healthy brain tissue, making it particularly suitable for patients with multiple brain metastases. The combination of gamma knife radiosurgery with biological and immunological agents is also gaining traction. For example, Elekta's combination therapy for melanoma brain metastases, which pairs immunotherapy with gamma knife radiosurgery, has shown improved tumor control and patient survival, highlighting the potential for combination treatments to drive market growth.

Regulatory Approvals and New Product Launches

The gamma knife market is further supported by regulatory approvals and the introduction of innovative products. For instance, Elekta introduced the Icon in May 2022, a gamma knife system that revolutionized the field by offering frameless, mask-based radiosurgery. This system has been particularly impactful in regions like Australia, where it has expanded the brain SRS capacity for treating neurological diseases, boosting market growth.

Market Challenges:

High Cost of Gamma Knife Radiotherapy Machines Coupled with Low Awareness of Patients

One of the significant challenges facing the gamma knife market is the high cost of gamma knife machines and the associated investment and maintenance expenses. The initial cost of gamma knife machines is considerably higher than other radiation equipment, which limits adoption in emerging economies. For instance, gamma knife surgery in India starts at USD 6,500, while in Western countries, the price ranges from USD 40,000 to USD 70,000. Additionally, the cobalt-60 radiation source used in gamma knife machines costs between USD 1 million to USD 2 million and requires replacement every five years, contributing to the overall expense.

The market's growth is also hindered by the limited availability of gamma knife machines outside of the Americas and Europe, as well as a shortage of skilled professionals capable of operating the equipment. Furthermore, general awareness of gamma knife treatment remains low, with many patients either unaware of the benefits or harboring misconceptions about the procedure. This lack of awareness and understanding is expected to slow down the market's growth, particularly in regions with limited access to advanced healthcare technologies.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the global gamma knife market?
• Which consumer segments are leading the adoption of gamma knife treatments?
• How are advancements in radiosurgery technology influencing the competitive landscape?
• Who are the key players in the global gamma knife market, and what strategies are they employing to maintain their market position?
• What are the emerging trends and future prospects in the global gamma knife market?

Competitive Intelligence and Business Strategy:

Leading players in the global gamma knife market, such as Elekta AB, Varian Medical Systems, and Accuray Incorporated, are focusing on product innovation, strategic collaborations, and expanding their geographical presence to maintain a competitive edge. These companies are investing heavily in research and development to create advanced gamma knife systems that offer improved precision and patient outcomes. Collaborations with healthcare providers and government agencies are enhancing market credibility and driving the adoption of these technologies. Additionally, targeted marketing and educational campaigns are crucial for increasing patient awareness and acceptance of gamma knife treatments.

Key Companies Profiled:

• Elekta AB
• Varian Medical Systems
• Huiheng Medical, Inc.
• MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.
• Akesis Inc.
• Cyber Medical Corporation Limited.
• Masep Infini Global, Inc.
• Nordion, Inc.
• Hokai
• ET Medical Group
• American Shared Hospital Services

Key Segments Covered in Gamma Knife Industry Research

Disease Indication:

• Brain Metastasis
• Cancer
• Arteriovenous Malformation (AVM)
• Trigeminal Neuralgia
• Others

Organ Treated:

• Head
• Neck
• Others

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Technology Roadmap
• 1.5. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Product Innovation / Development Trends

4. Key Success Factors

• 4.1. Product Adoption / Usage Analysis
• 4.2. Product USPs / Features
• 4.3. Install Base Scenario
• 4.4. Technology Assessment
• 4.5. Regulatory Landscape
• 4.6. PESTLE Analysis
• 4.7. Porter Analysis
• 4.8. Value Chain Analysis

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Expenditure Outlook
  • 5.1.3. Global Radiotherapy Market Outlook
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Prevalence of Obesity
  • 5.2.2. Demand for Non-Invasive Procedures
  • 5.2.3. Growing Burden of Brain Cancer
  • 5.2.4. Increasing Instances of Neurological Disorders
  • 5.2.5. Introduction of Novel Treatment Options
  • 5.2.6. Technological Advancements
  • 5.2.7. Product Adoption Rate
  • 5.2.8. Growing Installed Base
• 5.3. Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis - Impact Assessment

• 6.1. COVID-19 and Impact Analysis
  • 6.1.1. By Disease Indication
  • 6.1.2. By Organ Treated
  • 6.1.3. By Region
• 6.2. 2024 Market Scenario

7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2032

• 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2019-2023 and Forecast 2024-2032, By Disease Indication

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Mn) Analysis By Disease Indication, 2019-2023
• 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Indication, 2024-2032
  • 8.3.1. Brain Metastasis
  • 8.3.2. Cancer
  • 8.3.3. Arteriovenous Malformation (AVM)
  • 8.3.4. Trigeminal Neuralgia
  • 8.3.5. Others
• 8.4. Market Attractiveness Analysis By Disease Indication

9. Global Market Analysis 2019-2023 and Forecast 2024-2032, By Organ Treated

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Mn) Analysis By Organ Treated, 2019-2023
• 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Organ Treated, 2024-2032
  • 9.3.1. Head
  • 9.3.2. Neck
  • 9.3.3. Others
• 9.4. Market Attractiveness Analysis By Organ Treated

10. Global Market Analysis 2019-2023 and Forecast 2024-2032, by Region

• 10.1. Introduction
• 10.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
• 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2032
  • 10.3.1. North America
  • 10.3.2. Latin America
  • 10.3.3. Europe
  • 10.3.4. South Asia
  • 10.3.5. East Asia
  • 10.3.6. Oceania
  • 10.3.7. Middle East and Africa (MEA)
• 10.4. Market Attractiveness Analysis By Region

11. North America Market Analysis 2019-2023 and Forecast 2024-2032

• 11.1. Introduction
• 11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
  • 11.3.1. By Country
    • 11.3.1.1. U.S.
    • 11.3.1.2. Canada
  • 11.3.2. By Disease Indication
  • 11.3.3. By Organ Treated
• 11.4. Market Attractiveness Analysis
  • 11.4.1. By Country
  • 11.4.2. By Disease Indication
  • 11.4.3. By Organ Treated
• 11.5. Country Level Analysis & Forecast
  • 11.5.1. U.S. Market Analysis
    • 11.5.1.1. Introduction
    • 11.5.1.2. Market Analysis and Forecast by Market Taxonomy
      • 11.5.1.2.1. By Disease Indication
      • 11.5.1.2.2. By Organ Treated
  • 11.5.2. Canada Market Analysis
    • 11.5.2.1. Introduction
    • 11.5.2.2. Market Analysis and Forecast by Market Taxonomy
      • 11.5.2.2.1. By Disease Indication
      • 11.5.2.2.2. By Organ Treated
• 11.6. Market Trends
• 11.7. Key Market Participants - Intensity Mapping
• 11.8. Drivers and Restraints - Impact Analysis

12. Latin America Market Analysis 2019-2023 and Forecast 2024-2032

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
  • 12.3.1. By Country
    • 12.3.1.1. Brazil
    • 12.3.1.2. Mexico
    • 12.3.1.3. Argentina
    • 12.3.1.4. Rest of Latin America
  • 12.3.2. By Disease Indication
  • 12.3.3. By Organ Treated
• 12.4. Market Attractiveness Analysis
  • 12.4.1. By Country
  • 12.4.2. By Disease Indication
  • 12.4.3. By Organ Treated
• 12.5. Country Level Analysis & Forecast
  • 12.5.1. Brazil Market Analysis
    • 12.5.1.1. Introduction
    • 12.5.1.2. Market Analysis and Forecast by Market Taxonomy
      • 12.5.1.2.1. By Disease Indication
      • 12.5.1.2.2. By Organ Treated
  • 12.5.2. Mexico Market Analysis
    • 12.5.2.1. Introduction
    • 12.5.2.2. Market Analysis and Forecast by Market Taxonomy
      • 12.5.2.2.1. By Disease Indication
      • 12.5.2.2.2. By Organ Treated
  • 12.5.3. Argentina Market Analysis
    • 12.5.3.1. Introduction
    • 12.5.3.2. Market Analysis and Forecast by Market Taxonomy
      • 12.5.3.2.1. By Disease Indication
      • 12.5.3.2.2. By Organ Treated
• 12.6. Market Trends
• 12.7. Key Market Participants - Intensity Mapping
• 12.8. Drivers and Restraints - Impact Analysis

13. Europe Market Analysis 2019-2023 and Forecast 2024-2032

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
  • 13.3.1. By Country
    • 13.3.1.1. Germany
    • 13.3.1.2. France
    • 13.3.1.3. Italy
    • 13.3.1.4. U.K.
    • 13.3.1.5. Spain
    • 13.3.1.6. Russia
    • 13.3.1.7. BENELUX
    • 13.3.1.8. Nordic Countries
    • 13.3.1.9. Rest of Europe
  • 13.3.2. By Disease Indication
  • 13.3.3. By Organ Treated
• 13.4. Market Attractiveness Analysis
  • 13.4.1. By Country
  • 13.4.2. By Disease Indication
  • 13.4.3. By Organ Treated
• 13.5. Country Level Analysis & Forecast
  • 13.5.1. Germany Market Analysis
    • 13.5.1.1. Introduction
    • 13.5.1.2. Market Analysis and Forecast by Market Taxonomy
      • 13.5.1.2.1. By Disease Indication
      • 13.5.1.2.2. By Organ Treated
  • 13.5.2. France Market Analysis
    • 13.5.2.1. Introduction
    • 13.5.2.2. Market Analysis and Forecast by Market Taxonomy
      • 13.5.2.2.1. By Disease Indication
      • 13.5.2.2.2. By Organ Treated
  • 13.5.3. Italy Market Analysis
    • 13.5.3.1. Introduction
    • 13.5.3.2. Market Analysis and Forecast by Market Taxonomy
      • 13.5.3.2.1. By Disease Indication
      • 13.5.3.2.2. By Organ Treated
  • 13.5.4. U.K. Market Analysis
    • 13.5.4.1. Introduction
    • 13.5.4.2. Market Analysis and Forecast by Market Taxonomy
      • 13.5.4.2.1. By Disease Indication
      • 13.5.4.2.2. By Organ Treated
  • 13.5.5. Spain Market Analysis
    • 13.5.5.1. Introduction
    • 13.5.5.2. Market Analysis and Forecast by Market Taxonomy
      • 13.5.5.2.1. By Disease Indication
      • 13.5.5.2.2. By Organ Treated
  • 13.5.6. Russia Market Analysis
    • 13.5.6.1. Introduction
    • 13.5.6.2. Market Analysis and Forecast by Market Taxonomy
      • 13.5.6.2.1. By Disease Indication
      • 13.5.6.2.2. By Organ Treated
  • 13.5.7. Nordic Countries Market Analysis
    • 13.5.7.1. Introduction
    • 13.5.7.2. Market Analysis and Forecast by Market Taxonomy
      • 13.5.7.2.1. By Disease Indication
      • 13.5.7.2.2. By Organ Treated
  • 13.5.8. BENELUX Market Analysis
    • 13.5.8.1. Introduction
    • 13.5.8.2. Market Analysis and Forecast by Market Taxonomy
      • 13.5.8.2.1. By Disease Indication
      • 13.5.8.2.2. By Organ Treated
• 13.6. Market Trends
• 13.7. Key Market Participants - Intensity Mapping
• 13.8. Drivers and Restraints - Impact Analysis

14. South Asia Market Analysis 2019-2023 and Forecast 2024-2032

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
  • 14.3.1. By Country
    • 14.3.1.1. India
    • 14.3.1.2. Thailand
    • 14.3.1.3. Indonesia
    • 14.3.1.4. Malaysia
    • 14.3.1.5. Rest of South Asia
  • 14.3.2. By Disease Indication
  • 14.3.3. By Organ Treated
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Disease Indication
  • 14.4.3. By Organ Treated
• 14.5. Country Level Analysis & Forecast
  • 14.5.1. India Market Analysis
    • 14.5.1.1. Introduction
    • 14.5.1.2. Market Analysis and Forecast by Market Taxonomy
      • 14.5.1.2.1. By Disease Indication
      • 14.5.1.2.2. By Organ Treated
  • 14.5.2. Thailand Market Analysis
    • 14.5.2.1. Introduction
    • 14.5.2.2. Market Analysis and Forecast by Market Taxonomy
      • 14.5.2.2.1. By Disease Indication
      • 14.5.2.2.2. By Organ Treated
  • 14.5.3. Indonesia Market Analysis
    • 14.5.3.1. Introduction
    • 14.5.3.2. Market Analysis and Forecast by Market Taxonomy
      • 14.5.3.2.1. By Disease Indication
      • 14.5.3.2.2. By Organ Treated
  • 14.5.4. Malaysia Market Analysis
    • 14.5.4.1. Introduction
    • 14.5.4.2. Market Analysis and Forecast by Market Taxonomy
      • 14.5.4.2.1. By Disease Indication
      • 14.5.4.2.2. By Organ Treated
• 14.6. Market Trends
• 14.7. Key Market Participants - Intensity Mapping
• 14.8. Drivers and Restraints - Impact Analysis

15. East Asia Market Analysis 2019-2023 and Forecast 2024-2032

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
  • 15.3.1. By Country
    • 15.3.1.1. China
    • 15.3.1.2. Japan
    • 15.3.1.3. South Korea
  • 15.3.2. By Disease Indication
  • 15.3.3. By Organ Treated
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Country
  • 15.4.2. By Disease Indication
  • 15.4.3. By Organ Treated
• 15.5. Country Level Analysis & Forecast
  • 15.5.1. China Market Analysis
    • 15.5.1.1. Introduction
    • 15.5.1.2. Market Analysis and Forecast by Market Taxonomy
      • 15.5.1.2.1. By Disease Indication
      • 15.5.1.2.2. By Organ Treated
  • 15.5.2. Japan Market Analysis
    • 15.5.2.1. Introduction
    • 15.5.2.2. Market Analysis and Forecast by Market Taxonomy
      • 15.5.2.2.1. By Disease Indication
      • 15.5.2.2.2. By Organ Treated
  • 15.5.3. South Korea Market Analysis
    • 15.5.3.1. Introduction
    • 15.5.3.2. Market Analysis and Forecast by Market Taxonomy
      • 15.5.3.2.1. By Disease Indication
      • 15.5.3.2.2. By Organ Treated
• 15.6. Market Trends
• 15.7. Key Market Participants - Intensity Mapping
• 15.8. Drivers and Restraints - Impact Analysis

16. Oceania Market Analysis 2019-2023 and Forecast 2024-2032

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
  • 16.3.1. By Country
    • 16.3.1.1. Australia
    • 16.3.1.2. New Zealand
  • 16.3.2. By Disease Indication
  • 16.3.3. By Organ Treated
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By Disease Indication
  • 16.4.3. By Organ Treated
• 16.5. Country Level Analysis & Forecast
  • 16.5.1. Australia Market Analysis
    • 16.5.1.1. Introduction
    • 16.5.1.2. Market Analysis and Forecast by Market Taxonomy
      • 16.5.1.2.1. By Disease Indication
      • 16.5.1.2.2. By Organ Treated
  • 16.5.2. New Zealand Market Analysis
    • 16.5.2.1. Introduction
    • 16.5.2.2. Market Analysis and Forecast by Market Taxonomy
      • 16.5.2.2.1. By Disease Indication
      • 16.5.2.2.2. By Organ Treated
• 16.6. Market Trends
• 16.7. Key Market Participants - Intensity Mapping
• 16.8. Drivers and Restraints - Impact Analysis

17. Middle East and Africa Market Analysis 2019-2023 and Forecast 2024-2032

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
  • 17.3.1. By Country
    • 17.3.1.1. GCC Countries
    • 17.3.1.2. Turkiye
    • 17.3.1.3. Northern Africa
    • 17.3.1.4. South Africa
    • 17.3.1.5. Rest of Middle East and Africa
  • 17.3.2. By Disease Indication
  • 17.3.3. By Organ Treated
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Disease Indication
  • 17.4.3. By Organ Treated
• 17.5. Country Level Analysis & Forecast
  • 17.5.1. GCC Countries Market Analysis
    • 17.5.1.1. Introduction
    • 17.5.1.2. Market Analysis and Forecast by Market Taxonomy
      • 17.5.1.2.1. By Disease Indication
      • 17.5.1.2.2. By Organ Treated
  • 17.5.2. Turkiye Market Analysis
    • 17.5.2.1. Introduction
    • 17.5.2.2. Market Analysis and Forecast by Market Taxonomy
      • 17.5.2.2.1. By Disease Indication
      • 17.5.2.2.2. By Organ Treated
  • 17.5.3. Northern Africa Market Analysis
    • 17.5.3.1. Introduction
    • 17.5.3.2. Market Analysis and Forecast by Market Taxonomy
      • 17.5.3.2.1. By Disease Indication
      • 17.5.3.2.2. By Organ Treated
  • 17.5.4. South Africa Market Analysis
    • 17.5.4.1. Introduction
    • 17.5.4.2. Market Analysis and Forecast by Market Taxonomy
      • 17.5.4.2.1. By Disease Indication
      • 17.5.4.2.2. By Organ Treated
• 17.6. Market Trends
• 17.7. Key Market Participants - Intensity Mapping
• 17.8. Drivers and Restraints - Impact Analysis

18. Market Structure Analysis

• 18.1. Market Analysis by Tier of Companies
• 18.2. Market Share Analysis of Top Players
• 18.3. Market Presence Analysis

19. Competition Analysis

• 19.1. Competition Dashboard
• 19.2. Competition Benchmarking
• 19.3. Competition Deep Dive
  • 19.3.1. Elekta AB
    • 19.3.1.1. Overview
    • 19.3.1.2. Disease Indication Portfolio
    • 19.3.1.3. Key Financials
    • 19.3.1.4. Sales Footprint
    • 19.3.1.5. SWOT Analysis
    • 19.3.1.6. Strategy Overview
      • 19.3.1.6.1. Marketing Strategy
      • 19.3.1.6.2. Product Strategy
      • 19.3.1.6.3. Channel Strategy
  • 19.3.2. Varian Medical Systems
    • 19.3.2.1. Overview
    • 19.3.2.2. Disease Indication Portfolio
    • 19.3.2.3. Key Financials
    • 19.3.2.4. Sales Footprint
    • 19.3.2.5. SWOT Analysis
    • 19.3.2.6. Strategy Overview
      • 19.3.2.6.1. Marketing Strategy
      • 19.3.2.6.2. Product Strategy
      • 19.3.2.6.3. Channel Strategy
  • 19.3.3. Huiheng Medical, Inc.
    • 19.3.3.1. Overview
    • 19.3.3.2. Disease Indication Portfolio
    • 19.3.3.3. Key Financials
    • 19.3.3.4. Sales Footprint
    • 19.3.3.5. SWOT Analysis
    • 19.3.3.6. Strategy Overview
      • 19.3.3.6.1. Marketing Strategy
      • 19.3.3.6.2. Product Strategy
      • 19.3.3.6.3. Channel Strategy
  • 19.3.4. MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.
    • 19.3.4.1. Overview
    • 19.3.4.2. Disease Indication Portfolio
    • 19.3.4.3. Key Financials
    • 19.3.4.4. Sales Footprint
    • 19.3.4.5. SWOT Analysis
    • 19.3.4.6. Strategy Overview
      • 19.3.4.6.1. Marketing Strategy
      • 19.3.4.6.2. Product Strategy
      • 19.3.4.6.3. Channel Strategy
  • 19.3.5. Akesis Inc.
    • 19.3.5.1. Overview
    • 19.3.5.2. Disease Indication Portfolio
    • 19.3.5.3. Key Financials
    • 19.3.5.4. Sales Footprint
    • 19.3.5.5. SWOT Analysis
    • 19.3.5.6. Strategy Overview
      • 19.3.5.6.1. Marketing Strategy
      • 19.3.5.6.2. Product Strategy
      • 19.3.5.6.3. Channel Strategy
  • 19.3.6. Cyber Medical Corporation Limited.
    • 19.3.6.1. Overview
    • 19.3.6.2. Disease Indication Portfolio
    • 19.3.6.3. Key Financials
    • 19.3.6.4. Sales Footprint
    • 19.3.6.5. SWOT Analysis
    • 19.3.6.6. Strategy Overview
      • 19.3.6.6.1. Marketing Strategy
      • 19.3.6.6.2. Product Strategy
      • 19.3.6.6.3. Channel Strategy
  • 19.3.7. Masep Infini Global, Inc.
    • 19.3.7.1. Overview
    • 19.3.7.2. Disease Indication Portfolio
    • 19.3.7.3. Key Financials
    • 19.3.7.4. Sales Footprint
    • 19.3.7.5. SWOT Analysis
    • 19.3.7.6. Strategy Overview
      • 19.3.7.6.1. Marketing Strategy
      • 19.3.7.6.2. Product Strategy
      • 19.3.7.6.3. Channel Strategy
  • 19.3.8. Nordion, Inc.
    • 19.3.8.1. Overview
    • 19.3.8.2. Disease Indication Portfolio
    • 19.3.8.3. Key Financials
    • 19.3.8.4. Sales Footprint
    • 19.3.8.5. SWOT Analysis
    • 19.3.8.6. Strategy Overview
      • 19.3.8.6.1. Marketing Strategy
      • 19.3.8.6.2. Product Strategy
      • 19.3.8.6.3. Channel Strategy
  • 19.3.9. Hokai
    • 19.3.9.1. Overview
    • 19.3.9.2. Disease Indication Portfolio
    • 19.3.9.3. Key Financials
    • 19.3.9.4. Sales Footprint
    • 19.3.9.5. SWOT Analysis
    • 19.3.9.6. Strategy Overview
      • 19.3.9.6.1. Marketing Strategy
      • 19.3.9.6.2. Product Strategy
      • 19.3.9.6.3. Channel Strategy
  • 19.3.10. ET Medical Group
    • 19.3.10.1. Overview
    • 19.3.10.2. Disease Indication Portfolio
    • 19.3.10.3. Key Financials
    • 19.3.10.4. Sales Footprint
    • 19.3.10.5. SWOT Analysis
    • 19.3.10.6. Strategy Overview
      • 19.3.10.6.1. Marketing Strategy
      • 19.3.10.6.2. Product Strategy
      • 19.3.10.6.3. Channel Strategy
  • 19.3.11. American Shared Hospital Services
    • 19.3.11.1. Overview
    • 19.3.11.2. Disease Indication Portfolio
    • 19.3.11.3. Key Financials
    • 19.3.11.4. Sales Footprint
    • 19.3.11.5. SWOT Analysis
    • 19.3.11.6. Strategy Overview
      • 19.3.11.6.1. Marketing Strategy
      • 19.3.11.6.2. Product Strategy
      • 19.3.11.6.3. Channel Strategy

20. Assumptions and Acronyms Used

21. Research Methodology

관련자료